Back كوف إیران بركة Arabic COVIran Barekat Catalan COVIran Barekat Czech COVIran Barakat Spanish کوو ایران برکت Persian COVIran Barekat French COVIran Barakat ID 코비란 바레캇 코로나19 백신 Korean COVIran Barakat Russian COVIran Barekat SIMPLE
 A vial of COVIran Barakat | |
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Other names | BIV1-CovIran[1] COVIran Barakat COVIran Barkat کووایران برکت |
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status |
Full and emergency authorizations Full list of COVIran Barekat authorizations |
| Identifiers | |
| CAS Number | |
COVIran Barekat[3] (Persian: کووایران برکت) is a COVID-19 vaccine developed in Iran by Shifa Pharmed Industrial Group, a subsidiary of the Barkat Pharmaceutical Group.[4][5][6] It is an inactivated virus-based vaccine.[3] Iranian authorities have authorized its emergency use. This makes it the first locally developed COVID-19 vaccine to be approved for emergency use in the Middle East.[7]
Officials in charge say they are in the process to publish the results of the clinical trials in a peer-reviewed journal.[8] The interim results of the phases 1 and 2 trials showed 93.5% (95% CI, 88.4–99.6%) of the receivers of the vaccine have produced neutralizing antibodies against SARS-CoV-2.[9] Those results have not been peer-reviewed and describe the immunogenicity of the vaccine and not its efficacy. On 3 March 2022, peer-reviewed results have been published in the Clinical Microbiology and Infection.[10] [further explanation needed]
As of February 27, 2022, approximately 60 million doses have been produced according to Shifa Pharmed's CEO.[11] and the annual production capacity of this vaccine has reached 350 million doses.[12] Multiple Iranian personalities have received the vaccine, including the Supreme Leader, Ali Khamenei[5] and the President, Ebrahim Raisi.[13]
A version of the vaccine based on the Omicron variant and named CovIran Barkat Plus is in development and studied to be given as a third dose.[14][15]
- ^ Cite error: The named reference
:10was invoked but never defined (see the help page). - ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ a b Mallapaty S (August 2021). "Iran hopes to defeat COVID with home-grown crop of vaccines". Nature. 596 (7873): 475. Bibcode:2021Natur.596..475M. doi:10.1038/d41586-021-02216-z. PMID 34404947. S2CID 237198729.
- ^ Motamedi M (29 December 2020). "COVIran Barakat: Iran launches human trials of its COVID vaccine". Al Jazeera. Archived from the original on 31 January 2021.
- ^ a b "Iran's leader gets locally made coronavirus vaccine shot". Reuters. 2021-06-25. Retrieved 2021-08-24.
- ^ "About - شرکت گروه صنایع شفافارمد". 2021-04-15. Retrieved 2021-09-03.
- ^ Baghishov E (14 June 2021). "Iran issues license on its coronavirus vaccine". Trend.Az. Archived from the original on 2021-06-14. Retrieved 14 June 2021.
- ^ Cite error: The named reference
Tasnim_2021was invoked but never defined (see the help page). - ^ Setad (EIKO) (2021-06-16). "خلاصه نتایج تست انسانی واکسن کوو ایران برکت" [Summary of the results of COVIran Barekat vaccine's clinical trials] (PDF). Retrieved 2021-09-05.
- ^ Cite error: The named reference
:15was invoked but never defined (see the help page). - ^ "تولید ۶۰ میلیون دُز واکسن برکت در شفافارمد/ آغاز مطالعه بالینی واکسن اختصاصی اُمیکرون | خبرگزاری فارس" [Production of 60 million doses of Barakat vaccine in Shafafarmed / Initiation of clinical study of Omicron specific vaccine]. www.farsnews.ir (in Persian). 2022-02-26. Retrieved 2022-02-27.
- ^ The production capacity of the Barakat vaccine reached 350 million doses per year Tasnimnews.com, Retrieved 26 April 2022
- ^ Cite error: The named reference
:21was invoked but never defined (see the help page). - ^ "Iranian-made vaccine against Omicron begins clinical trial". Tehran Times. 2022-03-02. Retrieved 2022-03-03.
- ^ "IRCT | A Clinical trial to evaluate the immunogenicity and safety of Omicron-Based CovIran Barkat vaccine as a third injection dose in vaccinated population over 18 years of age". en.irct.ir. Retrieved 2022-03-03.